Theravance Inc. (THRX) said that telavancin received a favorable recommendation from the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration for the proposed indication to treat complicated skin and skin structure infections caused by Gram-positive bacteria, including resistant pathogens such as methicillin-resistant Staphylococcus aureus.
The Committee said that the data presented demonstrate the safety and effectiveness of telavancin for treatment of cSSSIs.
The Committee also said that there are specific clinical situations in which the benefits of telavancin use in pregnant women with cSSSI would outweigh the risks, and that a risk management strategy is needed to prevent unintended use of telavancin in pregnant women or women of child-bearing potential.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.